Carestream Unveils Next Generation Detector in Long-Length Digital Imaging

Carestream Health announces new innovations in its long-length imaging digital radiography (DR) detector that are aimed at improving patient comfort, productivity and efficiency.

The CARESTREAM DRX-LC Detector (Pending FDA 510(k) clearance) captures long-bone and spine images with a single exposure, making it ideal for pediatric imaging and long-bone and spine images of people with limited mobility. In contrast, the traditional multi-shot approach requires three to five exposures followed by manipulation and stitching of the images.

There are several key advancements in this next-generation long-length detector. The first is compatibility with DR mobile systems and mobile retrofits, in addition to X-ray rooms and room retrofits. The mobility of the system and its X-Factor capability allow facilities to use the same detector across multiple DRX systems for all phases of surgical treatment, from pre-planning imaging in the radiology department to capturing images during the procedure in the OR to confirm placement, and for post-operative assessment.

The versatile detector can be wireless or tethered. The wireless option eliminates trip hazards in the OR and minimizes the risk of contamination. The DRX-LC Detector has a Cesium (CsI) scintillator for better dose efficiency.

“Hospitals and clinics are looking for a better way to conduct long-length imaging exams that allow for lower dose, quicker exams and fewer repeats. The DRX-LC helps to minimize patient discomfort as the hold time is drastically reduced,” said Jill Hamman, Worldwide Marketing Manager, Global X-ray Solutions, at Carestream. “Its single shot ability also lowers radiation dose and the number of retakes due to patient movement. Further, an increase in image quality and precision provide a higher level of diagnostic confidence when planning treatment.”

The DRX-LC Detector uses ImageView Software, powered by Eclipse, the engine behind the company’s cutting-edge software platform that uses proprietary algorithms and artificial intelligence to amplify the value of the entire imaging chain.

The DRX-LC Detector meets the needs of a variety of facilities—from those that conduct several long-length exams to sites that see a high volume of patients.

“Single-shot long-length imaging delivers tangible improvements in patient comfort and workflow efficiency,” Ms. Hamman said. “The new wireless design, expanded system compatibility and mobile capacity of the DRX-LC Detector lets facilities expand their use of the system, maximizing their investment and bringing the benefits to more users.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”